Europe
Life sciences and pharma companies strengthen their leadership teams and board with this week’s Movers & Shakers.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 30, 2020.
AstraZeneca and the University of Oxford have partnered on the global development and distribution of Oxford’s COVID-19 vaccine it is developing.
Zejula, GlaxoSmithKline’s once-daily PARP inhibitor, won regulatory approval as a monotherapy maintenance treatment for women with advanced ovarian cancer whose disease is responsive to first-line platinum-based chemotherapy, regardless of biomarker status.
ADC Therapeutics SA, a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent antibody drug conjugates for patients suffering from hematological malignancies and solid tumors, announced the appointment of Victor Sandor, M.D., to its Board of Directors.
Biopharma companies from across the globe provide updates on their business and pipelines.
Together, the companies will focus on the generation of novel small molecule inhibitors against specified deubiquitinase (DUB) targets, specifically for the treatment of neurodegenerative and other diseases.
Pfizer and Germany-based BioNTech are collaborating on a messenger RNA vaccine against SARS-CoV-2, the novel coronavirus that causes COVID-19.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 29, 2020.
With the trillions of antibodies the human body can make, finding the antibody with the right combination of potency against a target and ease of manufacturing is, at best, an arduous, time-intensive endeavor for drug developers. AbCellera Biologics has developed a way to dramatically speed that process.
PRESS RELEASES